Dr Krishna M. Ella is the Founder and CMD of Bharat Biotech incorporated in 1996 . A PhD from University of Wisconsin-Madison and research scientist in Molecular Biology, he firmly believed to work on neglected diseases that turn into pandemic. He solved public healthcare problems caused by infectious diseases by developing vaccines. Bharat Biotech under his leadership stands as a global vaccine leader. His innovative entrepreneurship ventured into veterinary vaccines, food processing and multidimensional biotechnology infrastructure.

HIS Contribution to Healthcare Landscape in India;

* More than 16 and highest number of 11 viral vaccines in the developing world.
* World's cheapest and preservative free Revac-B, a hepatitis-B vaccine at 1 dollar.
* World's first WHO pre-qualified Typhoid Conjugate vaccine.
* Most affordable Rotavirus (ROTAVAC) vaccine.
* India's first cell-cultured Swine Flu vaccine.
* First vaccine for Chikungunya and Zika viruses.
* Supplying world's largest Rabies vaccine.
* Over 65 global patents and over $ 200 million into R & D.
* Biovet-animal health vaccine.

Change-Making Positions Held ;

Dr. Krishna Ella is charting science education and policy of India by associating with:
* Scientific Advisory Committee to the Cabinet.
* Governing Councils of CSIR and CCMB.
* Research Council for SIR National Laboratories.
* Board of Visitors-Global Health Institute, University of Wisconsin-Madison.

Laurels Brought to Dr Krishna M. Ella ;

* University of Southern California-Asia-Pacific Leadership Award.
* BioAsia-Genome Valley Excellence Award in 2021.
* National Research Service Award.
* Best Technology and Innovation Award by the Government of India.
* J. R. D. Tata-Best Entrepreneur of the Year Award in 2012.
* Rotary International Prize.

Impact Brought in the Lives of Indians and to People Worldwide ;

India's primacy in vaccine development and production is reinforced by Dr Krishna Ella's vision of vaccines for deadly diseases. In record time Bharat Biotech developed and sold more than nine billion of India's first indigenously developed COVAXIN winning hearts, saving lives and generating trust in the efficacy of its researchand vaccines.